NVCR News and Press, NovoCure Limited From 07/25/19

NovoCure ( NVCR ) Q2 results : Revenues: $86.7M (+41.0%). More news on: NovoCure Limited, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

NovoCure (NASDAQ: NVCR ): Q2 GAAP EPS of -$0.01 beats by $0.06 . More news on: NovoCure Limited, Earnings news and commentary, Healthcare stocks news, Read more ...

Quarterly net revenues of $86.7 million, representing 41 percent growth versus the second quarter 2018 The NovoTTF-100L™ System FDA approved to treat malignant pleural mesothelioma in combination with standard chemotherapies, Novocure’s first FDA-approved torso indication...

AAL , AAN , AB , ABB , AEP , AIMC , ALKS , ALLE , APD , ARD , ASPS , AUO , AXE , AZN , BANC , BAX , BC , BGCP , BMY , BUD , BWA , CCJ , CFR , CMCSA , CMS , COLB , CPG , CRI , CRR , CVE , DBD , DLX , ENTG , EQT , FAF , FCN , FDC , GLOP , GPI , GRA , H...

Introduction I first introduced the story of NovoCure ( NVCR ) in November 2017 when shares were trading below $20. Today, shares of NovoCure trade near $70. I was interested in NovoCure's new modality to treat cancer: the use of tumor treating fields that work to upset broken &am...

The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference Novocure (NASDAQ: NVCR) today announced 10 oral presentations and a special session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biolog...

Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune. Additional details on the fee schedule amount and pricing methodology are available on the CMS website . The announcement by C...

Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have released a final local coverage determination (LCD) providing coverage of Optune for Medicare beneficiaries with newly diagnosed glioblastoma (GBM) effective Se...

Zai Lab is a Chinese biotech company mainly focuses on oncology. It licenses in innovative drugs and medical devices from various US partners and tries to get CFDA approval and commercialization in China. Examples of such pipelines are niraparib from GSK (previously Tesaro), Optune from Novocu...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2019 on Thursday, July 25, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended...